Skip to main content

Table 1 Patient characteristics

From: Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial

  Morphine group
(n = 45)
Placebo group
(n = 45)
Patient characteristics
 Age, ya 59.9 ± 13.2 56.5 ± 10.6
 Male/female, n (%) 36 (80.0)/9 (20.0) 37 (82.2)/8 (17.8)
 Diabetes mellitus, n (%) 8 (17.8) 5 (11.1)
 Hypercholesterolemia, n (%) 14 (31.1) 13 (28.9)
 Smokers (current or former), n (%) 33 (73.3) 31 (68.8)
 Hypertension, n (%) 20 (44.4) 16 (35.6)
 Body mass index, kg/m2 a 27.0 ± 4.1 26.0 ± 2.9
Medical history, n (%)
 History of coronary artery disease 4 (8.9) 4 (8.9)
 History of heart failure 0 (0.0) 0 (0.0)
Clinical characteristics
 Symptom-to-balloon time, mina 189 ± 87 193 ± 108
 Killip class > 1, n (%) 1 (2.2) 1 (2.2)
 Sustained ventricular arrhythmia before admission, n (%) 0 (0.0) 2 (4.4)
Location of the culprit lesion, n (%)
 Left anterior descending artery 23 (51.1) 20 (44.4)
 Circumflex coronary artery 4 (8.9) 8 (17.8)
 Right coronary artery 18 (40.0) 17 (37.8)
Rentrop score, n (%)
 0 28 (62.2) 29 (64.5)
 1 10 (22.2) 10 (22.2)
 2–3 7 (15.6) 6 (13.3)
Number of diseased vessels, n (%)
 1 34 (75.6) 36 (80.0)
  ≥ 2 11 (24.4) 9 (20.0)
Concomitant therapy, n (%)
 Aspirin 45 (100.0) 44 (97.8)
 P2Y12 receptor blockers 44 (97.8) 44 (97.8)
 GPIIb-IIIa receptor inhibitors/bilavirudin 22(48.9)/20(44.4) 26(57.7)/16(35.6)
 Intravenous morphine injection 11 (24.4) 11 (24.4)
  1. aMean ± SD